{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:17:46Z","timestamp":1771877866517,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,7]],"date-time":"2015-03-07T00:00:00Z","timestamp":1425686400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s12032-015-0549-3","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T06:03:13Z","timestamp":1425621793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors"],"prefix":"10.1007","volume":"32","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ti","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,7]]},"reference":[{"key":"549_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"549_CR2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"549_CR3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00432-003-0511-1","volume":"130","author":"ZY Tang","year":"2004","unstructured":"Tang ZY, Ye SL, Liu YK, et al. A decade\u2019s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:187\u201396.","journal-title":"J Cancer Res Clin Oncol"},{"key":"549_CR4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"549_CR5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"549_CR6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5582\/ddt.2014.01031","volume":"8","author":"J Chen","year":"2014","unstructured":"Chen J, Gao J. Advances in the study of molecularly targeted agents to treat hepatocellular carcinoma. Drug Discov Ther. 2014;8:154\u201364.","journal-title":"Drug Discov Ther"},{"key":"549_CR7","first-page":"164","volume":"7","author":"Y Zhong","year":"2013","unstructured":"Zhong Y, Liu B, Deng M, Xu R. Adjuvant systemic drug therapy and recurrence of hepatocellular carcinoma following curative resection. Drug Discov Ther. 2013;7:164\u20136.","journal-title":"Drug Discov Ther"},{"key":"549_CR8","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1002\/cncr.24673","volume":"115","author":"C Printz","year":"2009","unstructured":"Printz C. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer. 2009;115:4646.","journal-title":"Cancer"},{"key":"549_CR9","first-page":"137","volume":"7","author":"Z Wang","year":"2014","unstructured":"Wang Z, Zhang G, Wu J, Jia M. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect. Drug Discov Ther. 2014;7:137\u201343.","journal-title":"Drug Discov Ther"},{"key":"549_CR10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.5582\/bst.2014.01120","volume":"8","author":"W Zhang","year":"2014","unstructured":"Zhang W, Zhao G, Wei K, et al. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. BioScience Trends. 2014;8:333\u20138.","journal-title":"BioScience Trends"},{"key":"549_CR11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/fon.09.136","volume":"6","author":"CS Roxburgh","year":"2010","unstructured":"Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149\u201363.","journal-title":"Future Oncol"},{"key":"549_CR12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2012.06.022","volume":"57","author":"DJ Pinato","year":"2012","unstructured":"Pinato DJ, Stebbing J, Ishizuka M, et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57:1013\u201320.","journal-title":"J Hepatol"},{"key":"549_CR13","first-page":"619","volume":"32","author":"M Morimoto","year":"2012","unstructured":"Morimoto M, Numata K, Moriya S, et al. Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. Anticancer Res. 2012;32:619\u201323.","journal-title":"Anticancer Res"},{"key":"549_CR14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00535-009-0050-x","volume":"44","author":"MJ Ju","year":"2009","unstructured":"Ju MJ, Qiu SJ, Fan J, et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child\u2013Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44:635\u201342.","journal-title":"J Gastroenterol"},{"key":"549_CR15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5582\/ddt.2014.01025","volume":"8","author":"Z Wang","year":"2014","unstructured":"Wang Z, Song P, Xia J, Inagaki Y, Tang W, Kokudo N. Can gamma-glutamyl transferase levels contribute to a better prognosis for patients with hepatocellular carcinoma? Drug Discov Ther. 2014;8:134\u20138.","journal-title":"Drug Discov Ther"},{"key":"549_CR16","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1038\/bjc.2013.598","volume":"109","author":"S Balta","year":"2013","unstructured":"Balta S, Demirkol S, Unlu M, Arslan Z, Celik T. Neutrophil to lymphocyte ratio may be predict of mortality in all conditions. Br J Cancer. 2013;109:3125\u20136.","journal-title":"Br J Cancer"},{"key":"549_CR17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/SLA.0b013e318297ad6b","volume":"258","author":"Y Mano","year":"2013","unstructured":"Mano Y, Shirabe K, Yamashita Y, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 2013;258:301\u20135.","journal-title":"Ann Surg"},{"key":"549_CR18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12032-014-0969-5","volume":"31","author":"K Wei","year":"2014","unstructured":"Wei K, Wang M, Zhang W, Mu H, Song TQ. Neutrophil\u2013lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Med Oncol. 2014;31:969.","journal-title":"Med Oncol"},{"key":"549_CR19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jss.2014.05.078","volume":"192","author":"W Peng","year":"2014","unstructured":"Peng W, Li C, Wen TF, et al. Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival. J Surg Res. 2014;192:402\u20138.","journal-title":"J Surg Res"},{"key":"549_CR20","doi-asserted-by":"crossref","first-page":"e58184","DOI":"10.1371\/journal.pone.0058184","volume":"8","author":"J Dan","year":"2013","unstructured":"Dan J, Zhang Y, Peng Z, et al. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS ONE. 2013;8:e58184.","journal-title":"PLoS ONE"},{"key":"549_CR21","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.3748\/wjg.v11.i45.7109","volume":"11","author":"S Bo","year":"2005","unstructured":"Bo S, Gambino R, Durazzo M, et al. Associations between gamma-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: a possible implication for oxidative stress. World J Gastroenterol. 2005;11:7109\u201317.","journal-title":"World J Gastroenterol"},{"key":"549_CR22","first-page":"1","volume":"7","author":"P Song","year":"2014","unstructured":"Song P, Feng X, Zhang K, et al. Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepatocellular carcinoma in China. Biosci Trends. 2014;7:1\u20136.","journal-title":"Biosci Trends"},{"key":"549_CR23","first-page":"1410","volume":"46","author":"YJ Lee","year":"2008","unstructured":"Lee YJ, Kim JK, Lee JH, Lee HR, Kang DR, Shim JY. Association of serum gamma-glutamyltransferase with C-reactive protein levels and white blood cell count in Korean adults. Clin Chem Lab Med. 2008;46:1410\u20135.","journal-title":"Clin Chem Lab Med"},{"key":"549_CR24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.numecd.2006.10.002","volume":"18","author":"Y Saijo","year":"2008","unstructured":"Saijo Y, Utsugi M, Yoshioka E, et al. The relationship of gamma-glutamyltransferase to C-reactive protein and arterial stiffness. Nutr Metab Cardiovasc Dis. 2008;18:211\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"549_CR25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.atherosclerosis.2004.08.027","volume":"178","author":"DH Lee","year":"2005","unstructured":"Lee DH, Jacobs DR Jr. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis. 2005;178:327\u201330.","journal-title":"Atherosclerosis"},{"key":"549_CR26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1440-1746.2011.06910.x","volume":"27","author":"TM Chen","year":"2012","unstructured":"Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol. 2012;27:553\u201361.","journal-title":"J Gastroenterol Hepatol"},{"key":"549_CR27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.juro.2011.10.026","volume":"187","author":"Y Ohno","year":"2012","unstructured":"Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol. 2012;187:411\u20137.","journal-title":"J Urol"},{"key":"549_CR28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2011.09.001","volume":"48","author":"D Keizman","year":"2012","unstructured":"Keizman D, Ish-Shalom M, Huang P, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 2012;48:202\u20138.","journal-title":"Eur J Cancer"},{"key":"549_CR29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12032-013-0556-1","volume":"30","author":"M Kobayashi","year":"2013","unstructured":"Kobayashi M, Kubo T, Komatsu K, et al. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol. 2013;30:556.","journal-title":"Med Oncol"},{"key":"549_CR30","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1200\/JCO.2007.15.6521","volume":"26","author":"XD Zhu","year":"2008","unstructured":"Zhu XD, Zhang JB, Zhuang PY, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707\u201316.","journal-title":"J Clin Oncol"},{"key":"549_CR31","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2890","volume":"18","author":"Y Sun","year":"2012","unstructured":"Sun Y, Campisi J, Higano C, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012;18:1359\u201368.","journal-title":"Nat Med"},{"key":"549_CR32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrc3588","volume":"13","author":"S Seton-Rogers","year":"2013","unstructured":"Seton-Rogers S. Tumour microenvironment: means of resistance. Nat Rev Cancer. 2013;13:607.","journal-title":"Nat Rev Cancer"},{"key":"549_CR33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrclinonc.2012.127-c1","volume":"10","author":"S Masuda","year":"2013","unstructured":"Masuda S, Izpisua Belmonte JC. The microenvironment and resistance to personalized cancer therapy. Nat Rev Clin Oncol. 2013;10:64.","journal-title":"Nat Rev Clin Oncol"},{"key":"549_CR34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2012.08.017","volume":"58","author":"T Motomura","year":"2013","unstructured":"Motomura T, Shirabe K, Mano Y, et al. Neutrophil\u2013lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58:58\u201364.","journal-title":"J Hepatol"},{"key":"549_CR35","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-09-2904","volume":"16","author":"W Zhang","year":"2010","unstructured":"Zhang W, Zhu XD, Sun HC, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res. 2010;16:3420\u201330.","journal-title":"Clin Cancer Res"},{"key":"549_CR36","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/hep.22506","volume":"48","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312\u201327.","journal-title":"Hepatology"},{"key":"549_CR37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","volume":"16","author":"ZG Fridlender","year":"2009","unstructured":"Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN. Cancer Cell. 2009;16:183\u201394.","journal-title":"Cancer Cell"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0549-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-015-0549-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0549-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T14:36:24Z","timestamp":1566398184000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-015-0549-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s12032-015-0549-3","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,7]]},"article-number":"107"}}